Researchers validate the REDMOD AI framework, which detects early, otherwise invisible, tissue changes of pancreatic cancer on CT scans before clinical diagnosis.
Key Details
- 1REDMOD is an AI radiomics model for detecting subtle texture changes indicative of stage 0 pancreatic ductal adenocarcinoma on CT.
- 2The model identified preclinical disease an average of 475 days before clinical diagnosis.
- 3In head-to-head comparison, REDMOD's sensitivity was nearly double that of expert radiologists (73% vs. 39%).
- 4Performance remained high (68% vs. 23%) for cancers detected over two years before diagnosis.
- 5The model showed strong generalisability in external cohorts (correctly identifying >81% and 87.5% of cases in independent datasets).
- 6Researchers caution further prospective validation and testing in high-risk patients are needed before clinical adoption.
Why It Matters
Ultra-early detection of pancreatic cancer could dramatically improve survival rates by enabling treatment before symptoms arise. AI models like REDMOD may soon provide radiologists with powerful new tools to catch deadly cancers in their most treatable phases.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.